Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene

Abstract From the Canadian patent

Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C D and/or V ORF(s) , is reduced or ablated by modifying a recombinant PIV genome or antigenome for , example by introduction of a stop codon by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon or , by a frame shift mutation in the targeted ORF(s). Alternatively the C, D , and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein …